ISSN:
1569-8041
Schlagwort(e):
cisplatin
;
combination chemotherapy
;
gemcitabine
;
pancreatic cancer
;
prolonged survival
Quelle:
Springer Online Journal Archives 1860-2000
Thema:
Medizin
Notizen:
Abstract Background:This phase II study was initiated to determine theefficacy and safety of gemcitabine plus cisplatin in patients with pancreaticcancer. Patients and methods:Gemcitabine 1000 mg/m2 was givenon days 1, 8, and 15 of a 28-day schedule, and cisplatin 50 mg/m2on days 1 and 15 to chemonaive patients with locally advanced or metastaticpancreatic cancer. Results:Of the 41 patients enrolled (median age 57, and61% male), median Karnofsky performance status was 80%. Patientsreceived a median of 4.2 cycles (range 1–11). In 35 evaluable patients,one complete response (CR) and three partial responses (PR) were observed, foran overall response rate of 11% (95% confidence interval(95% CI): 3.2%–26.7%). Stable disease (SD) 〉3months occurred in 20 (57%) patients; 6 survived ≥1 year. Mediantime to progressive disease was 4.3 months (95% CI: 3.0–5.7months). For all patients, median survival was 8.2 months (95% CI:6.1–10.6 months) with a one-year survival rate of 27%. Therapywas well tolerated. Grade 3–4 neutropenia (no grade 3–4infection), thrombocytopenia (no bleeding), nausea/vomiting, and alopecia werereported in 29%, 13%, and 2.6% of patients, respectively. Conclusions:The combination of gemcitabine and cisplatin is amoderately active treatment for patients with locally advanced and metastaticpancreatic cancer without compromising tolerability.
Materialart:
Digitale Medien
URL:
http://dx.doi.org/10.1023/A:1026595525977
Permalink